GBA's "2021 Stock Phantasma"

idea 2- MQ @$27 BUY BUY BUY!

Folks it's time for Marqeta! There was a lot of excitement yesterday in the BNPL space!
Our beloved AFRM roared ahead.... but there is a secondary player you may want to keep an eye on..... Marqeta.

Marqeta works with Afterpay & Square!

I see MQ as a backdoor Crypto play. Goldman Sachs is developing a digital wallet and they are partnering with Marqeta.

Affirm's stock "will now include an M&A premium," Bernstein's Harshita Rawat wrote in a note to clients. In her view, the deal announcement translates to a negative read for PayPal Holdings Inc.PYPL,-1.65%,which also has expanded into BNPL and is seeing a 0.2% drop in its stock during Monday's session. She saw a positive read through for Marqeta Inc.MQ,+1.30%,which works with both Afterpay and Square on debit-based products


idea 3- Confluent, Inc. (CFLT)- best performer on my board yest- do not own!
NasdaqGS - NasdaqGS Real Time Price. Currency in USD

41.54+2.35 (+6.00%)
At close:

 
--Aqua Metals announces successful completion of 3rd generation Aqualyzer 08:27 AQMS

--Beam Global receives order for ten EV ARC off-grid EV charging systems 08:20 BEEM

--Mindset files international patent application for psilocybin synthesis method 08:20 MSSTF

--Biohaven Pharmaceutical price target raised to $150 from $101 at Canaccord 08:12 BHVN

--Ralph Lauren reports Q1 adjusted EPS $2.29, consensus 86c 08:12 RL

--Arcturus Therapeutics receives approval for CTA from Singapore HSA 07:58 ARCT Arcturus Therapeutics announced that the company has received approval for a clinical trial application, or CTA, from the Singapore Health Sciences Authority, or HSA, to enable the advancement of two STARR mRNA vaccine candidates into the clinic. The Phase 1/2 clinical trial will evaluate the vaccines both as a primary vaccination series and as a booster following initial vaccination with Comirnaty. The Phase 1/2 trial costs are funded in part from a previously secured grant from Singapore.
 
--Morgan Stanley starts Iridium at Overweight with $50 price target 07:50 IRDM

--Joint Corp. price target raised to $105 from $65 at B. Riley » 07:49 JYNT

--Truist assumes 'first of a kind warehousing pureplay' GXO Logistics at Buy 07:27 GXO, XPO As previously reported, Truist analyst Stephanie Moore assumed coverage of GXO Logistics (GXO) with a Buy rating and $100 price target after its completed spin-off from XPO Logistics (XPO). The analyst states that as a stand-alone company, GXO is the "first of its kind pure play" on warehousing and distribution, with the spinoff allowing for greater financial flexibility and control to capitalize on the growth of outsourced logistics, e-commerce, and automation. Moore adds that GXO is in the "early innings" of margin improvement as its tech investments "bear fruit".
 
stonedinvestor said:
--Aqua Metals announces successful completion of 3rd generation Aqualyzer 08:27 AQMS

--Beam Global receives order for ten EV ARC off-grid EV charging systems 08:20 BEEM

--Mindset files international patent application for psilocybin synthesis method 08:20 MSSTF

--Biohaven Pharmaceutical price target raised to $150 from $101 at Canaccord 08:12 BHVN

--Ralph Lauren reports Q1 adjusted EPS $2.29, consensus 86c 08:12 RL

--Arcturus Therapeutics receives approval for CTA from Singapore HSA 07:58 ARCT Arcturus Therapeutics announced that the company has received approval for a clinical trial application, or CTA, from the Singapore Health Sciences Authority, or HSA, to enable the advancement of two STARR mRNA vaccine candidates into the clinic. The Phase 1/2 clinical trial will evaluate the vaccines both as a primary vaccination series and as a booster following initial vaccination with Comirnaty. The Phase 1/2 trial costs are funded in part from a previously secured grant from Singapore.
More...

Hey you realize Aqua Metals is not AQUA right?

AQMS was one you were hooting about at $4.20

stonedinvestor said:
AQMS is moving faster than I can track it or buy it.

$4.08 open to over $4.50>>> $4.20 now.
More...

I bit my tongue and was nice btw, albeit I warned ya.
It's $2.20 now.
:rolleyes:
 
I'm tempted to pull RBLX out of the Gummies-4-Grandma Portfolio Stoney.

That thing is sooooo priced to perfection, and there is no way this China bs isn't going to sting.

They don't break out revenue by country, but the dude flat out said China is where the growth is.
No friggin way China lets RBLX continue to operate there.
If not for the "opium of the mind" thing, then by the mere fact that they maintain data on the kids that play it. That has been the crux of this whole movement.

$RBLX is out of the G4G portfolio at $78.
 
--OpGen achieves development milestone in Unyvero A30 RQ platform program 07:37 OPGN

--Baozun price target lowered to $36 from $57 at Citi 06:27 BZUN Citi analyst Alicia Yap lowered the firm's price target on Baozun to $36 from $57 and keeps a Buy rating on the shares ahead of the company's Q2 results. The analyst expects the company's gross merchandise volume growth will be intact following the impact from the cotton incident but says its sportswear and apparel sales will likely weigh on monetization. Hence she sees potentially slower revenue growth. However, Baozun shares largely reflect any near-term headwinds, Yap tells investors in a research note.

--https://www.youtube.com/watch?v=O6oCvJYH0qs
 
vanzandt said:
I'm tempted to pull RBLX out of the Gummies-4-Grandma Portfolio Stoney.

That thing is sooooo priced to perfection, and there is no way this China bs isn't going to sting.

They don't break out revenue by country, but the dude flat out said China is where the growth is.
No friggin way China lets RBLX continue to operate there.
If not for the "opium of the mind" thing, then by the mere fact that they maintain data on the kids that play it. That has been the crux of this whole movement.

$RBLX is out of the G4G portfolio at $78.
More...


Is SNAP in or out??
 
You must log in or register to reply here.
Back
Top